What does MEDICAL PRACTICE AND RESEARCH do?

MEDICAL PRACTICE AND RESEARCH is a general practice in Ukkel. Private Limited, started on 19 June 1996.

What is the address of MEDICAL PRACTICE AND RESEARCH?

The registered office of MEDICAL PRACTICE AND RESEARCH is located at Montjoielaan 83, 1180 Ukkel.

Is MEDICAL PRACTICE AND RESEARCH still active?

Yes. According to the CBE (29 September 2026) MEDICAL PRACTICE AND RESEARCH is active, legal situation “Normale toestand”, started on 19 June 1996.

Is MEDICAL PRACTICE AND RESEARCH registered on Peppol?

No, MEDICAL PRACTICE AND RESEARCH is currently not registered on the Peppol network.

What is the enterprise number of MEDICAL PRACTICE AND RESEARCH?

The enterprise number of MEDICAL PRACTICE AND RESEARCH is BE0458268580.

When was MEDICAL PRACTICE AND RESEARCH founded?

MEDICAL PRACTICE AND RESEARCH was founded on 19 June 1996.

Who are the directors of MEDICAL PRACTICE AND RESEARCH?

According to the 2025 annual accounts, the directors of MEDICAL PRACTICE AND RESEARCH are: Pierre BRIHAYE.

Is MEDICAL PRACTICE AND RESEARCH a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 June 1996; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did MEDICAL PRACTICE AND RESEARCH make in 2025?

MEDICAL PRACTICE AND RESEARCH recorded a loss after taxes of € 23,925 in financial year 2025.

What is the revenue of MEDICAL PRACTICE AND RESEARCH?

As a small company, MEDICAL PRACTICE AND RESEARCH is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 66,342.

MEDICAL PRACTICE AND RESEARCH (Private Limited) - Ukkel

Dossier MEDICAL PRACTICE AND RESEARCH, printed on 29 September 2026 from databakkes.be/en/0458268580/medical-practice-and-research. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

MEDICAL PRACTICE AND RESEARCH from Ukkel, company number BE0458268580, closed financial year 2025 with a result of € -23,925 after tax. For that financial year MEDICAL PRACTICE AND RESEARCH recorded a gross margin of € 66,342 and equity of € 441,725. Compared with financial year 2024, the result moved from € -45,640 to € -23,925. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Healthy

€ 441,725

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -23,925

▲ 48 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 307,837

▲ 166% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 429,325.

People and assets in 2025

Wage cost

€ 36,877

▼ 6% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 25,892

▼ 20% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,316

▼ 66% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 11,874

▼ 52% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 137,658 Gross margin 2022: € 137,658 First fiscal year in the series	€ 101,362 Gross margin 2023: € 101,362 ▼ 26% vs 2022 (€ 137,658) Unfavourable step	€ 44,165 Gross margin 2024: € 44,165 ▼ 56% vs 2023 (€ 101,362) Unfavourable step	€ 66,342 Gross margin 2025: € 66,342 ▲ 50% vs 2024 (€ 44,165) Favourable step	▲ 50%
Profit after taxes	€ 38,168 Profit after taxes 2022: € 38,168 First fiscal year in the series	€ 12,518 Profit after taxes 2023: € 12,518 ▼ 67% vs 2022 (€ 38,168) Unfavourable step	€ -45,640 Profit after taxes 2024: € -45,640 ▼ € 58,158 vs 2023 (€ 12,518) Unfavourable step	€ -23,925 Profit after taxes 2025: € -23,925 ▲ € 21,715 vs 2024 (€ -45,640) Favourable step	▲ € 21,715
Equity	€ 498,771 Equity 2022: € 498,771 First fiscal year in the series	€ 511,290 Equity 2023: € 511,290 ▲ 3% vs 2022 (€ 498,771) Favourable step	€ 465,650 Equity 2024: € 465,650 ▼ 9% vs 2023 (€ 511,290) Unfavourable step	€ 441,725 Equity 2025: € 441,725 ▼ 5% vs 2024 (€ 465,650) Unfavourable step	▼ 5%
Total debts	€ 43,137 Total debts 2022: € 43,137 First fiscal year in the series	€ 89,728 Total debts 2023: € 89,728 ▲ 108% vs 2022 (€ 43,137) Unfavourable step	€ 57,794 Total debts 2024: € 57,794 ▼ 36% vs 2023 (€ 89,728) Favourable step	€ 30,217 Total debts 2025: € 30,217 ▼ 48% vs 2024 (€ 57,794) Favourable step	▼ 48%
Cash	€ 288,127 Cash 2022: € 288,127 First fiscal year in the series	€ 392,944 Cash 2023: € 392,944 ▲ 36% vs 2022 (€ 288,127) Favourable step	€ 115,685 Cash 2024: € 115,685 ▼ 71% vs 2023 (€ 392,944) Unfavourable step	€ 307,837 Cash 2025: € 307,837 ▲ 166% vs 2024 (€ 115,685) Favourable step	▲ 166%
Land & buildings	€ 196,654 Land & buildings 2022: € 196,654 First fiscal year in the series	€ 172,631 Land & buildings 2023: € 172,631 ▼ 12% vs 2022 (€ 196,654) Unchanged	€ 151,459 Land & buildings 2024: € 151,459 ▼ 12% vs 2023 (€ 172,631) Unchanged	€ 121,592 Land & buildings 2025: € 121,592 ▼ 20% vs 2024 (€ 151,459) Unchanged	▼ 20%
Retained profit	€ 486,371 Retained profit 2022: € 486,371 First fiscal year in the series	€ 498,890 Retained profit 2023: € 498,890 ▲ 3% vs 2022 (€ 486,371) Favourable step	€ 453,250 Retained profit 2024: € 453,250 ▼ 9% vs 2023 (€ 498,890) Unfavourable step	€ 429,325 Retained profit 2025: € 429,325 ▼ 5% vs 2024 (€ 453,250) Unfavourable step	▼ 5%
Balance sheet total	€ 541,908 Balance sheet total 2022: € 541,908 First fiscal year in the series	€ 601,018 Balance sheet total 2023: € 601,018 ▲ 11% vs 2022 (€ 541,908) Unchanged	€ 523,444 Balance sheet total 2024: € 523,444 ▼ 13% vs 2023 (€ 601,018) Unchanged	€ 471,941 Balance sheet total 2025: € 471,941 ▼ 10% vs 2024 (€ 523,444) Unchanged	▼ 10%

Key figures of MEDICAL PRACTICE AND RESEARCH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDICAL PRACTICE AND RESEARCH?

What happened at MEDICAL PRACTICE AND RESEARCH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: loss of € 23,925. filed late Source: NBB ↗
Jun 19, 1996 Start of the company according to the CBE. KBO

In short

From € 38,168 profit in 2022 to € 23,925 loss in 2025.

Paid € 22,753 in corporate taxes since 2022.

Best year ever: 2022, with € 38,168 profit.

Original PDFs at the National Bank ↗

A new publication or filing at MEDICAL PRACTICE AND RESEARCH? We notify you, reason included.

Follow MEDICAL PRACTICE AND RESEARCH

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Pierre BRIHAYE

MEDICAL PRACTICE AND RESEARCH

Behind MEDICAL PRACTICE AND RESEARCH is Pierre BRIHAYE.

See the full network in the app

Directors

According to the 2025 annual accounts

Pierre BRIHAYE

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Montjoielaan 83

1180 Ukkel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0458.268.580
VAT number: BE 0458.268.580
Registered office: Montjoielaan 83, 1180 Ukkel
Names & denominations: MEDICAL PRACTICE AND RESEARCH · M.P.R.
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 June 1996
Peppol: Not registered
Activities · NACE: Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗